Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study

Title:	First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
Authors:	Qin, Shukui^{Aff1, Aff2, IDs12325024030694_cor1}; Bai, Yuxian^Aff3; Li, Jin^Aff4; Pan, Hongming^Aff5; Luo, Suxia^Aff6; Qu, Yanli^Aff7; Ye, Feng^Aff8; Yang, Lin^Aff9; Liu, Tianshu^Aff10; Li, Wei^Aff11; Chen, Xi^Aff12; Yang, Jianwei^Aff13; Ying, Jieer^Aff14; Lin, Xiaoyan^Aff15; Zhao, Lin^Aff16; Liang, Xinjun^Aff17; Mao, Yixiang^Aff18; Guo, Run^Aff19; Zuo, Yi^Aff19; Bordia, Sonal^Aff20; Li, Shouguo^Aff21
Source:	Advances in Therapy. 42(4):1892-1906
Database:	Springer Nature Journals